Optical coherence tomography assessment of disease activity in cryopyrin-associated periodic syndrome.

NLRP3 variants OCT autoinflammation

Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
16 Apr 2024
Historique:
revised: 18 03 2024
received: 26 01 2024
accepted: 28 03 2024
medline: 17 4 2024
pubmed: 17 4 2024
entrez: 17 4 2024
Statut: aheadofprint

Résumé

Cryopyrin-associated periodic syndrome is a rare autoinflammatory disease caused by gain-of-function mutations or variants in the NLRP3 gene. Clinically, patients suffer from a broad spectrum of both systemic and neurological symptoms. The aim of this study was to determine whether systemic inflammation demonstrated by serum amyloid A (SAA) elevation is associated with neuroinflammation assessed by optical coherence tomography (OCT). Thirty eyes of 15 patients with NLRP3 low penetrance mutations (PwNLRP3) and 20 eyes of 10 age- and sex-matched healthy controls were examined by spectral-domain OCT as part of routine clinical care. All retinal layers and clinical features were evaluated. At baseline no significant retinal neuroaxonal inflammation or degeneration was observed in all measured retinal layers amongst PwNLRP3 compared with healthy controls. In a pooled analysis of all individual OCT time points a significant difference regarding the macular retinal nerve fibre layer was detected. Increased levels of SAA showed a positive association with averaged combined outer plexiform layer and outer nuclear layer volumes (ρ < 0.0001, r In cryopyrin-associated periodic syndrome increased combined outer plexiform layer and outer nuclear layer volumes are mirrored by SAA increase, an acute phase reactant indicating systemic inflammation. Our findings identify OCT as a candidate biomarker to monitor subclinical neuroinflammation and to assess disease activity in PwNLRP3.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Cryopyrin-associated periodic syndrome is a rare autoinflammatory disease caused by gain-of-function mutations or variants in the NLRP3 gene. Clinically, patients suffer from a broad spectrum of both systemic and neurological symptoms. The aim of this study was to determine whether systemic inflammation demonstrated by serum amyloid A (SAA) elevation is associated with neuroinflammation assessed by optical coherence tomography (OCT).
METHODS METHODS
Thirty eyes of 15 patients with NLRP3 low penetrance mutations (PwNLRP3) and 20 eyes of 10 age- and sex-matched healthy controls were examined by spectral-domain OCT as part of routine clinical care. All retinal layers and clinical features were evaluated.
RESULTS RESULTS
At baseline no significant retinal neuroaxonal inflammation or degeneration was observed in all measured retinal layers amongst PwNLRP3 compared with healthy controls. In a pooled analysis of all individual OCT time points a significant difference regarding the macular retinal nerve fibre layer was detected. Increased levels of SAA showed a positive association with averaged combined outer plexiform layer and outer nuclear layer volumes (ρ < 0.0001, r
CONCLUSION CONCLUSIONS
In cryopyrin-associated periodic syndrome increased combined outer plexiform layer and outer nuclear layer volumes are mirrored by SAA increase, an acute phase reactant indicating systemic inflammation. Our findings identify OCT as a candidate biomarker to monitor subclinical neuroinflammation and to assess disease activity in PwNLRP3.

Identifiants

pubmed: 38628041
doi: 10.1111/ene.16301
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e16301

Informations de copyright

© 2024 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Références

Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin‐like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat Genet. 2001;29:301‐305.
Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821‐832.
Parker T, Keddie S, Kidd D, et al. Neurology of the cryopyrin‐associated periodic fever syndrome. Eur J Neurol. 2016;23:1145‐1151.
Mulazzani E, Wagner D, Havla J, et al. Neurological phenotypes in patients with NLRP3‐, MEFV‐, and TNFRSF1A low‐penetrance variants. J Neuroinflammation. 2020;17:196.
Schuh E, Lohse P, Ertl‐Wagner B, et al. Expanding spectrum of neurologic manifestations in patients with NLRP3 low‐penetrance mutations. Neurol Neuroimmunol Neuroinflamm. 2015;2:e109.
Cruz‐Herranz A, Balk LJ, Oberwahrenbrock T, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86:2303‐2309.
Schippling S, Balk LJ, Costello F, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR‐IB criteria. Mult Scler. 2015;21:163‐170.
Aytulun A, Cruz‐Herranz A, Aktas O, et al. APOSTEL 2.0 recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2021;97:68‐79.
Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78:1025‐1032.
Meng T, Wu D, Luo Y, et al. Ocular manifestations in Chinese adult patients with NLRP3‐associated autoinflammatory disease. Sci Rep. 2021;11:11904.
Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta‐analysis. Lancet Neurol. 2017;16:797‐812.
Sui A, Chen X, Shen J, et al. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL‐1beta/IL‐18 activation pattern in an oxygen‐induced ischemic retinopathy mouse model. Cell Death Dis. 2020;11:901.
Chen L, Yang P, Kijlstra A. Distribution, markers, and functions of retinal microglia. Ocul Immunol Inflamm. 2002;10:27‐39.
Puyang Z, Feng L, Chen H, Liang P, Troy JB, Liu X. Retinal ganglion cell loss is delayed following optic nerve crush in NLRP3 knockout mice. Sci Rep. 2016;6:20998.

Auteurs

E Mulazzani (E)

Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.

L Böhm (L)

Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.

T Christmann (T)

Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.

M Krumbholz (M)

Department of Neurology and Pain Treatment, Immanuel Klinik Rüdersdorf, University Hospital of the Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany.
Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany.
Department of Neurology and Stroke, University Hospital of Tübingen, Tübingen, Germany.

T Kümpfel (T)

Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.

J Havla (J)

Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.

Classifications MeSH